Calcium Gluceptate

Summary

Calcium Gluceptate (CHEMBL1237066) is an approved small molecule (ATC A12AA10).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A12AA10
• Chemistry: 490.42 Da · C14H26CaO16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237066
Name	Calcium Gluceptate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	62859
ChEBI	CHEBI:3314
ATC	A12AA10
Molecular formula	C14H26CaO16
Molecular weight	490.42
InChIKey	FATUQANACHZLRT-KMRXSBRUSA-L

SMILES: C([C@H]([C@H]([C@@H]([C@H](C(C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(C(=O)[O-])O)O)O)O)O)O.[Ca+2]

IUPAC name: calcium bis((3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate)

ChEBI definition: The calcium salt of (2ξ)-D-gluco-heptonic acid. It is used as a calcium supplement for treatment of hypocalcaemia.

Also known as: Calcium gluceptate, Calcium glucoheptonate, Calcium glucoheptonate (1:2), Calcium glucoheptone, Glucoheptonate de calcium, Glucoheptonato de calcio, NSC-755885, CALCIUM GLUCEPTATE

Patent coverage: 790 distinct patent families (1,676 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).